{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=combined+therapy+treatment&page=12",
    "query": {
      "intervention": "combined therapy treatment",
      "page": 12
    },
    "page_size": 10
  },
  "pagination": {
    "page": 12,
    "page_size": 10,
    "total_count": 12515,
    "total_pages": 1252,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=combined+therapy+treatment&page=13&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=combined+therapy+treatment&page=11&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-13T22:38:07.832Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01140282",
      "title": "Exercise Program for Early Breast Cancer Survivors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Stage I Breast Cancer",
        "Stage II Breast Cancer",
        "Stage IIIA Breast Cancer",
        "Stage IIIB Breast Cancer",
        "Stage IIIC Breast Cancer"
      ],
      "interventions": [
        {
          "name": "questionnaire administration",
          "type": "OTHER"
        },
        {
          "name": "quality-of-life assessment",
          "type": "PROCEDURE"
        },
        {
          "name": "management of therapy complications",
          "type": "PROCEDURE"
        },
        {
          "name": "exercise intervention",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "OTHER",
        "PROCEDURE",
        "BEHAVIORAL"
      ],
      "sponsor": "University of Southern California",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 106,
      "start_date": "2012-05-21",
      "completion_date": "2018-10-01",
      "has_results": false,
      "last_update_posted_date": "2019-06-18",
      "last_synced_at": "2026-10-13T22:38:07.832Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01140282"
    },
    {
      "nct_id": "NCT01964924",
      "title": "Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Metastatic Triple-Negative Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Estrogen Receptor Negative",
        "HER2/Neu Negative",
        "Invasive Breast Carcinoma",
        "Progesterone Receptor Negative",
        "Recurrent Breast Carcinoma",
        "Stage IV Breast Cancer",
        "Triple-Negative Breast Carcinoma"
      ],
      "interventions": [
        {
          "name": "Akt Inhibitor GSK2141795",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Trametinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 37,
      "start_date": "2013-10-02",
      "completion_date": "2018-04-23",
      "has_results": true,
      "last_update_posted_date": "2019-09-20",
      "last_synced_at": "2026-10-13T22:38:07.832Z",
      "location_count": 8,
      "location_summary": "Washington D.C., District of Columbia • Tampa, Florida • Buffalo, New York + 4 more",
      "locations": [
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Buffalo",
          "state": "New York"
        },
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01964924"
    },
    {
      "nct_id": "NCT05836324",
      "title": "A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Solid Tumors",
        "Advanced Solid Tumors",
        "Metastatic Solid Tumors"
      ],
      "interventions": [
        {
          "name": "INCA33890",
          "type": "DRUG"
        },
        {
          "name": "bevacizumab",
          "type": "DRUG"
        },
        {
          "name": "FOLFIRI",
          "type": "DRUG"
        },
        {
          "name": "FOLFOX",
          "type": "DRUG"
        },
        {
          "name": "Cetuximab",
          "type": "DRUG"
        },
        {
          "name": "ADG126",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Incyte Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 570,
      "start_date": "2023-07-24",
      "completion_date": "2029-05-03",
      "has_results": false,
      "last_update_posted_date": "2026-07-23",
      "last_synced_at": "2026-10-13T22:38:07.832Z",
      "location_count": 11,
      "location_summary": "Los Angeles, California • Boston, Massachusetts • Grand Rapids, Michigan + 7 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Grand Rapids",
          "state": "Michigan"
        },
        {
          "city": "Hackensack",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05836324"
    },
    {
      "nct_id": "NCT01084824",
      "title": "A Trial Examining the Treatment of Common Warts With Combination Liquid Nitrogen (LN2) and Cantharidin",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Verruca Vulgaris"
      ],
      "interventions": [
        {
          "name": "Liquid nitrogen and cantharidin",
          "type": "DRUG"
        },
        {
          "name": "Liquid nitrogen and topical placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "North Idaho Dermatology",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 70,
      "start_date": "2007-06",
      "completion_date": "2008-09",
      "has_results": false,
      "last_update_posted_date": "2010-03-11",
      "last_synced_at": "2026-10-13T22:38:07.832Z",
      "location_count": 1,
      "location_summary": "Coeur d'Alene, Idaho",
      "locations": [
        {
          "city": "Coeur d'Alene",
          "state": "Idaho"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01084824"
    },
    {
      "nct_id": "NCT04617496",
      "title": "An RCT of a Telemedicine Intervention for Hypokinetic Dysarthria in PD",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Parkinson's Disease"
      ],
      "interventions": [
        {
          "name": "Combined speech and exercise intervention",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Health education",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "VA Office of Research and Development",
      "sponsor_class": "FED",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "89 Years",
        "sex": "ALL",
        "summary": "40 Years to 89 Years"
      },
      "enrollment_count": 104,
      "start_date": "2021-07-01",
      "completion_date": "2025-04-30",
      "has_results": true,
      "last_update_posted_date": "2026-01-07",
      "last_synced_at": "2026-10-13T22:38:07.832Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04617496"
    },
    {
      "nct_id": "NCT04663061",
      "title": "Diabetes Data-Assisted Remission Trial (DDART)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Type 2 Diabetes",
        "Obesity"
      ],
      "interventions": [
        {
          "name": "Medical weight loss",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Diabetes education",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Continuous glucose monitoring",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Wake Forest University Health Sciences",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 64,
      "start_date": "2021-06-09",
      "completion_date": "2024-11-14",
      "has_results": true,
      "last_update_posted_date": "2026-04-03",
      "last_synced_at": "2026-10-13T22:38:07.832Z",
      "location_count": 1,
      "location_summary": "Winston-Salem, North Carolina",
      "locations": [
        {
          "city": "Winston-Salem",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04663061"
    },
    {
      "nct_id": "NCT02395042",
      "title": "A Safety and Efficacy Study of LiRIS® in Females With Interstitial Cystitis With Hunner's Lesions",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Cystitis, Interstitial",
        "Ulcer"
      ],
      "interventions": [
        {
          "name": "LiRIS®",
          "type": "DRUG"
        },
        {
          "name": "LiRIS Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Allergan",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 59,
      "start_date": "2015-04-15",
      "completion_date": "2017-11-20",
      "has_results": true,
      "last_update_posted_date": "2018-10-05",
      "last_synced_at": "2026-10-13T22:38:07.832Z",
      "location_count": 17,
      "location_summary": "Murrieta, California • Vacaville, California • Farmington, Connecticut + 14 more",
      "locations": [
        {
          "city": "Murrieta",
          "state": "California"
        },
        {
          "city": "Vacaville",
          "state": "California"
        },
        {
          "city": "Farmington",
          "state": "Connecticut"
        },
        {
          "city": "Alpharetta",
          "state": "Georgia"
        },
        {
          "city": "Annapolis",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02395042"
    },
    {
      "nct_id": "NCT05007873",
      "title": "ASTX727 and Dasatinib for the Treatment of Newly Diagnosed Philadelphia Chromosome or BCR-ABL Positive Chronic Myeloid Leukemia in Chronic Phase",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Chronic Phase Chronic Myelogenous Leukemia",
        "Philadelphia Chromosome Positive",
        "BCR-ABL1 Positive Chronic Myelogenous Leukemia",
        "BCR-ABL1 Positive"
      ],
      "interventions": [
        {
          "name": "Dasatinib",
          "type": "DRUG"
        },
        {
          "name": "Decitabine and Cedazuridine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 39,
      "start_date": "2021-10-21",
      "completion_date": "2028-10-30",
      "has_results": false,
      "last_update_posted_date": "2026-10-02",
      "last_synced_at": "2026-10-13T22:38:07.832Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05007873"
    },
    {
      "nct_id": "NCT02597673",
      "title": "Trial of Self-managed Approaches for Patellofemoral Pain Syndrome in Active Duty",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Patellofemoral Pain Syndrome"
      ],
      "interventions": [
        {
          "name": "Home Exercise Program (HEP)",
          "type": "OTHER"
        },
        {
          "name": "NMES",
          "type": "DEVICE"
        },
        {
          "name": "TENS",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "OTHER",
        "DEVICE"
      ],
      "sponsor": "University of Tennessee",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 132,
      "start_date": "2015-07",
      "completion_date": "2018-05-31",
      "has_results": true,
      "last_update_posted_date": "2020-10-01",
      "last_synced_at": "2026-10-13T22:38:07.832Z",
      "location_count": 1,
      "location_summary": "Fort Campbell North, Kentucky",
      "locations": [
        {
          "city": "Fort Campbell North",
          "state": "Kentucky"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02597673"
    },
    {
      "nct_id": "NCT01183169",
      "title": "Efficacy and Safety of Adding Alisporivir (DEB025) to Peginterferon (IFN) Alfa-2a (Peg-IFN Alfa-2a) and Ribavirin in Chronic HCV Genotype 1 Patients Who Relapsed or Did Not Respond to Previous Treatment",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hepatitis C"
      ],
      "interventions": [
        {
          "name": "Alisporivir",
          "type": "DRUG"
        },
        {
          "name": "Peginterferon alfa-2a",
          "type": "DRUG"
        },
        {
          "name": "Ribavirin",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Debiopharm International SA",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 459,
      "start_date": "2010-08",
      "completion_date": "2013-05",
      "has_results": true,
      "last_update_posted_date": "2016-08-25",
      "last_synced_at": "2026-10-13T22:38:07.832Z",
      "location_count": 18,
      "location_summary": "San Diego, California • Ventura, California • Bradenton, Florida + 13 more",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Ventura",
          "state": "California"
        },
        {
          "city": "Bradenton",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01183169"
    }
  ]
}